US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Caris Life Sciences, Inc. (CAI): VC-Backed AI TechBio Company Seeks $5b+ IPO Valuation

Caris Life Sciences, Inc. (CAI): Price Bumped Higher, Intersection of Cancer and AI in High Demand

Caris Life Sciences, Inc. (CAI): Peeking at the Prospectus of an AI TechBio IPO

IPOs and Secondary Offerings

Equity Capital Markets

Caris Life Sciences / Equity Capital Markets

<ul>
<li>The next-generation AI TechBio company priced a full size deal of 23.5mm shares at $21.00  and opened at $27.00 for a gain of 28.6% at first trade. </li>
<li>It was easy for IPO investors to wrap their heads around this company. Caris generates billions of data points and uses AI to customize immunotherapy for individuals.</li>
<li>Looking ahead, it is our opinion that this "could" be a company that investors tuck away in their portfolio for a long time.</li>
</ul>


The next-generation AI TechBio company priced a full size deal of 23.5mm shares at $21.00  and opened at $27.00 for a gain of 28.6% at first trade. 
It was easy for IPO investors to wrap their heads around this company. Caris generates billions of data points and uses AI to customize immunotherapy for individuals.
Looking ahead, it is our opinion that this "could" be a company that investors tuck away in their portfolio for a long time.


Caris Life Sciences, Inc. (CAI): AI Cancer TechBio Company Surges Six Points at Open